The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for the diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over.

Mounjaro is now authorised for adult patients with a BMI of 30kg/m² or more (obesity), as well as those with a BMI between 27-30kg/m² (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.

The medicine should be used together with a reduced-calorie diet and increased physical activity.

Tirzepatide, the active ingredient, works by regulating a patient’s appetite so they feel full.

Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said: "We have prioritised rapid assessment of this new indication for Mounjaro, given the public health importance of access to new medicines to help tackle obesity.

"We have drawn on advice from the independent Commission on Human Medicines in coming to our decision, and as with all products, will keep the safety of Mounjaro under close review.